Citations

Showing 10 of 108060 citations.

Cannabis Use in IBD Is Associated With Increased Healthcare Utilization but not With Surgery or Death
Loeb, Lauren , Kinnucan, Jami

Mayo Clinic

Inflammatory Bowel Diseases | August 15, 2023 | Volume: 30 | Issue: 7 | Pages: 1215-1217

10.1093/ibd/izad164 | PMID 37580879 Get It

Planetary Relationships to Birth (Imputed Conception) Rates in Humans: A Signature of Cosmic Origin?
Georgiopoulou, E., Hofmann, S. , Maroudas, Marios , Mastronikolis, Andreas , Matteson, Eric L. , Tsagri, M., Zioutas, K. , Maroudas, Marios , Hofmann, S.

Mayo Clinic

Biophysical Reviews and Letters | August 15, 2023 | Volume: 18 | Issue: 02 | Pages: 107-118

10.1142/s1793048023500029 Get It

This report addresses the time dependence of normal biomedical processes. The conception rate in humans shows relationships that strikingly coincide with planetary periodicities like the orbital period of Jupiter, the 11 years solar cycle and the 237 days Jupiter–Venus synod, and the combined dependence on Jupiter with Mars’ orbital position. The birth rates are used as conception surrogates based on a data set available from the Minnesota Department of Health. The statistical significance of each independent analysis (far) exceeds 5[Formula: see text]. This result cannot be explained with known science. As with other observations in Physics and Medicine (i.e., melanoma), tentatively the only viable explanation we have is the otherwise invisible streaming matter from the dark Universe we live in. The favored dark matter scenario involves streams or clusters as opposed to an isotropic dark sector. The dark Universe scenario has been the driving idea for this type of work. The high sensitivity of living matter to the tiniest external impact might help identify the nature of the dark matter particles, a major problem in all physics since the 1930s. This work is a model for evaluating other biological processes and mutation rates.
Efficacy of anti‐CD3 monoclonal antibodies in delaying the progression of recent‐onset type 1 diabetes mellitus: A systematic review, meta‐analyses and
Ashraf, Muhammad Talal , Rizvi, Syed Hassan Ahmed, Kashif, Muhammad Arham Bin , Asghar, Muhammad Sohaib , Asghar, Muhammad S , Khan, Muhammad Khuzzaim , Ahmed, Syed Hassan

Mayo Clinic

Diabetes, Obesity and Metabolism | August 15, 2023 | Volume: 25 | Issue: 11 | Pages: 3377-3389

10.1111/dom.15237 | PMID 37580969 Get It

Abstract Aim Type 1 diabetes mellitus is widely recognized as a chronic autoimmune disease characterized by the pathogenic destruction of beta cells, resulting in the loss of endogenous insulin production. Insulin administration remains the primary therapy for symptomatic treatment. Recent studies showed that disease‐modifying agents, such as anti‐CD3 monoclonal antibodies, have shown promising outcomes in improving the management of the disease. In late 2022, teplizumab received approval from the US Food and Drug Administration (FDA) as the first disease‐modifying agent for the treatment of type 1 diabetes. This review aims to evaluate the clinical evidence regarding the efficacy of anti‐CD3 monoclonal antibodies in the prevention and treatment of type 1 diabetes. Methods A comprehensive search of PubMed, Google Scholar, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) was conducted up to December 2022 to identify relevant randomized controlled trials. Meta‐analysis was performed using a random‐effects model, and odds ratios with 95% confidence intervals (CIs) were calculated to quantify the effects. The Cochrane risk of bias tool was employed for quality assessment. Results In total, 11 randomized controlled trials involving 1397 participants (908 participants in the intervention arm, 489 participants in the control arm) were included in this review. The mean age of participants was 15 years, and the mean follow‐up time was 2.04 years. Teplizumab was the most commonly studied intervention. Compared with placebo, anti‐CD3 monoclonal antibody treatment significantly increased the C‐peptide concentration in the area under the curve at shorter timeframes (mean difference = 0.114, 95% CI: 0.069 to 0.159, p = .000). Furthermore, anti‐CD3 monoclonal antibodies significantly reduced the patients' insulin intake across all timeframes (mean difference = −0.123, 95% CI: −0.151 to −0.094, p < .001). However, no significant effect on glycated haemoglobin concentration was observed. Conclusion The findings of this review suggest that anti‐CD3 monoclonal antibody treatment increases endogenous insulin production and improves the lifestyle of patients by reducing insulin dosage. Future studies should consider the limitations, including sample size, heterogeneity and duration of follow‐up, to validate the generalizability of these findings further.
Meeting the needs of the patient with non‐English language preference in the hospital setting
Brumbaugh, Jane E. , Tschida‐Reuter, Daniel J., Barwise, Amelia , Barwise, Amelia K , Brumbaugh, Jane E , Tschida-Reuter, Daniel

Mayo Clinic

Health Services Research | August 14, 2023 | Volume: 58 | Issue: 5 | Pages: 965-969

10.1111/1475-6773.14217 | PMID 37580055 Get It

Teaching Video NeuroImage: Inverted Patellar Reflex Localizes the Site of Spinal Epidural Arteriovenous Fistula
Schipani, Elke , Itoh, Christopher Y. , Klaas, James P. , Pinto, Marcus Vinícius , Schipani Bailey, Elke , Klaas, James P , Pinto, Marcus V , Lanzino, Giuseppe

Mayo Clinic

Neurology | August 14, 2023 | Volume: 101 | Issue: 17 | Pages: No page available

10.1212/wnl.0000000000207753 | PMID 37580167 Get It

Retrospective Evaluation of Neuropathologic Proxies of the Minimal Atrophy Subtype Compared With Corticolimbic Alzheimer Disease Subtypes
Boon, Baayla D.C. , Labuzan, Sydney A. , Peng, Zhongwei , Matchett, Billie J. , Hinkle, Kelly M., Lachner, Christian , Ross, Owen A. , Ertekin‐Taner, Nilüfer , Carter, Rickey E. , Ferman, Tanis J. , Duara, Ranjan , Graff‐Radford, Neill R. , Kouri, Naomi , Duara, Ranjan , Dickson, Dennis W , Murray, Melissa E , Ross, Owen A , Carter, Rickey E , Ferman, Tanis J , Dickson, Dennis W. , Murray, Melissa E.

Mayo Clinic

Neurology | August 14, 2023 | Volume: 101 | Issue: 14 | Pages: No page available

10.1212/wnl.0000000000207685 | PMID 37580158 Get It

Treatment of Ruptured Wide‐Necked Aneurysms using a Microcatheter Injectable Biomaterial
Zhang, Zefu , Albadawi, Hassan , Fowl, Richard J., Mayer, Joseph L. , Chong, Brian W. , Öklü, Rahmi , Oklu, Rahmi

Mayo Clinic

Advanced Materials | August 14, 2023 | Volume: 35 | Issue: 46 | Pages: No page available

10.1002/adma.202305868 | PMID 37579579 Get It

Abstract Ruptured wide‐neck aneurysms (WNAs), especially in a setting of coagulopathy, are associated with significant morbidity and mortality. It is shown that by trapping a sub‐millimeter clinical catheter inside the aneurysm sac using a flow diverter stent (FDS), instant hemostasis can be achieved by filling the aneurysm sac using a novel biomaterial, rescuing catastrophic bleeding in large‐animal models. Multiple formulations of a biomaterial comprising gelatin, nanoclay (NC), and iohexol are developed, optimized, and extensively tested in vitro to select the lead candidate for further testing in vivo in murine, porcine, and canine models of WNAs, including in a subset with aneurysm rupture. The catheter‐injectable and X‐ray visible versions of the gel embolic agent (GEA) with the optimized mechanical properties outperform control groups, including a subset that receive a clinically used liquid embolic (Onyx, Medtronic), with and without aneurysm rupture. A combinatorial approach to ruptured WNAs with GEA and FDS may change the standard of medical practice and save lives.
Urinary Proteomics for Discovery of Gastric Cancer Biomarkers to Enable Precision Clinical Oncology
Joshi, Neha , Bhat, Firdous Ahmad , Bellad, Anikha , Jain, Anu, Sirdeshmukh, Ravi, Pandey, Akhilesh , Bhat, Firdous, Chavan, Sandip , Pandey, Akhilesh , Bellad, Anikha , Joshi, Neha S , Sathe, Gajanan

Mayo Clinic

OMICS: A Journal of Integrative Biology | August 14, 2023 | Volume: 27 | Issue: 8 | Pages: 361-371

10.1089/omi.2023.0077 | PMID 37579183 Get It

For precision in clinical oncology practice, detection of tumor-derived peptides and proteins in urine offers an attractive and noninvasive alternative for diagnostic or screening purposes. In this study, we report comparative quantitative proteomic profiling of urine samples from patients with gastric cancer and healthy controls using tandem mass tags-based multiplexed mass spectrometry approach. We identified 1504 proteins, of which 246 were differentially expressed in gastric cancer cases. Notably, ephrin A1 (EFNA1), pepsinogen A3 (PGA3), sortilin 1 (SORT1), and vitronectin (VTN) were among the upregulated proteins, which are known to play crucial roles in the progression of gastric cancer. We also found other overexpressed proteins, including shisa family member 5 (SHISA5), mucin like 1 (MUCL1), and leukocyte cell derived chemotaxin 2 (LECT2), which had not previously been linked to gastric cancer. Using a novel approach for targeted proteomics, SureQuant, we validated changes in abundance of a subset of proteins discovered in this study. We confirmed the overexpression of vitronectin and sortilin 1 in an independent set of urine samples. Altogether, this study provides molecular candidates for biomarker development in gastric cancer, and the findings also support the promise of urinary proteomics for noninvasive diagnostics and personalized/precision medicine in the oncology clinic.
A 37-Year-Old Patient Presenting at 39 Weeks of Pregnancy with Thoracic Aortic Dissection Due to Previously Undiagnosed FBN1-Related Marfan Syndrome
Gurrieri, Carmelina , Manske, Westley T., Williams, Carla, Wildenberg, Joseph C. , Keppers, Rachel J., Saran, Nishant , Tallarita, Tiziano , Calvin, Andrew D , Wildenberg, Joseph , Williams, Carla, Calvin, Andrew D.

Mayo Clinic

American Journal of Case Reports | August 14, 2023 | Volume: 24 | Issue: No issue available | Pages: No page available

10.12659/ajcr.940628 | PMID 37743617 Get It